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combined with mizoribine during a period from August 
2006 to June 2010 (Group A; n = 34) and a three-course 
steroid pulse during a period from July 2010 to March 
2013 (Group B; n = 32). Primary end points were excre-
tory amounts of proteinuria, disappearance of proteinuria 
and hematuria, and exacerbation of renal function.
Results In both the groups, proteinuria decreased sig-
nificantly 12 months after treatment, and no significant 
difference in alleviation effects on proteinuria was found 
between groups. eGFR increased significantly 12 months 
after treatment in Group A, whereas it tended to decrease in 
Group B. As for the preservation effect on eGFR, Group A 
showed significantly higher preservation of eGFR. Similar 
results were shown in the patients whose eGFR at the start 
of the treatment was less than 60 mL/min/1.73 m2.
Conclusions Single-course steroid pulse therapy com-
bined with mizoribine was considered to have a protective 
effect on the renal function in IgA nephropathy, especially 
accompanying renal dysfunction.
Keywords IgA nephropathy · Tonsillectomy · Steroid 
pulse · Mizoribine
Introduction
IgA nephropathy was initially reported by Berger and 
Hinglais in 1968 [1]. Since then, a great deal of research 
regarding its etiology, pathologic conditions, and establish-
ment of treatment methods has been presented. Its clinical 
presentation is various, including natural remission cases, 
gradual progressions to renal failure in the terminal stage, 
and cases of rapid exacerbation of renal function. This var-
ied pathologic condition has prevented establishment of 
specific treatment methods.
Abstract 
Purpose It has been reported that steroid pulse therapy 
for IgA nephropathy improves renal prognosis. However, 
because of the side effects, steroid dose must be restricted 
to some cases. Treatment effects of steroid on cases already 
presenting with reduced renal function are unknown. In 
this study, we performed tonsillectomy in patients with IgA 
nephropathy and conducted a comparative study about sub-
sequent immunosuppressive therapy.
Methods Subjects were patients younger than 70 years 
of age diagnosed with IgA nephropathy by renal biopsy. 
Treatment protocols were a single-course steroid pulse 
 * Tomohiro Kaneko 
 tomohiro@nms.ac.jp
 Momoko Arai 
 takemomoko@nms.ac.jp
 Mariko Ikeda 
 maripon0107@yahoo.co.jp
 Megumi Morita 
 f-megumi@nms.ac.jp
 Yoko Watanabe 
 s9100@nms.ac.jp
 Akio Hirama 
 ahirama@nms.ac.jp
 Akira Shimizu 
 ashimizu@nms.ac.jp
 Shuichi Tsuruoka 
 tsuruoka@nms.ac.jp
1 Division of Nephrology, Department of Internal Medicine, 
Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, 
Tokyo 113-8603, Japan
2 Department of Analytic Human Pathology, Nippon Medical 
School, Tokyo, Japan
1824 Int Urol Nephrol (2015) 47:1823–1830
1 3
There have been many reports which state that steroid 
treatments are effective for inhibiting the progress of IgA 
nephropathy [2, 3]. However, in a randomized controlled 
trial (RCT) in which treatment using an oral steroid of 
20 mg/day for 2 years in patients with IgA nephropathy 
whose serum creatinine level was less than 1.5 mg/dL, 
although reduced proteinuria was found progress of renal 
dysfunction was not inhibited [4]. Pozzi et al. [5] conducted 
a multicenter study in subjects with IgA nephropathy hav-
ing proteinuria of 1.0–3.5 g/day and serum creatinine lev-
els of 1.5 mg/dL or less and reported that steroid therapy, 
including three-course pulse therapy, significantly inhibited 
the progress of renal dysfunction up to 10 years after treat-
ment. However, they also showed some cases where pro-
teinuria recurred after treatment and the need to give the 
same scheme occurred.
Combined treatment of steroid pulse therapy with bilat-
eral tonsillectomy has been performed mainly in Japan. 
There have been numerous reports demonstrating a high 
remission rate obtained by this treatment in early-stage 
cases [6–8]. Recently, a multicenter prospective study in 
IgA nephropathy cases with conditions identical to those 
in Pozzi et al. was conducted. Compared with three-course 
steroid pulse treatment only, steroid pulse therapy combined 
with tonsillectomy showed no significant difference in 
remission of the urinary findings, but 12 months following 
treatment resulted in significant reduction in proteinuria [9].
In cases where glomerular filtration rate (GFR) has 
already decreased, increases in sclerotic glomerulus as well 
as progress of interstitial fibrosis are pointed out with the 
high dose of steroid. Thus, in treating IgA nephropathy in 
CKD stage 3 or greater, renin–angiotensin system (RAS) 
inhibitors have been primarily used. However, effects of 
RAS treatment alone are insufficient. On the other hand, in 
the patients with progressive IgA nephropathy with serum 
creatinines of 1.5 mg/dL or higher, there has been a report 
stating that RCT by immunosuppressive therapy with oral 
steroids and cyclophosphamide and azathioprine decreased 
proteinuria and hematuria and inhibited the progress of 
renal dysfunction [10].
We previously reported that in IgA nephropathy with 
dominant chronic lesions and additional acute active 
lesions, after tonsillectomy, single-course steroid pulse 
therapy combined with mizoribine (MZR) resulted in 
improvement of the renal function [11, 12]. However, dif-
ferences in the treatment effects of different types of con-
ventional steroid pulse therapy combined with tonsillec-
tomy have not been clarified.
To answer this, 34 cases of single-course steroid pulse 
therapy + MZR and 32 cases of three-course steroid pulse 
therapy after tonsillectomy were compared for alleviation 
in hematuria and proteinuria and inhibitory effects in pro-
gress of renal dysfunction.
Materials and methods
Patients
Criteria for steroid pulse therapy combined with tonsil-
lectomy at our hospital are as follows: ① patients who are 
diagnosed IgA nephropathy by renal biopsy, ② patients 
who present persistent microscopic hematuria and pro-
teinuria, ③ patients whose estimated value of GFR (eGFR) 
is 20 mL/min/1.73 m2 or higher, ④ patients younger than 
70, ⑤ patients where general anesthesia is possible, and 
⑥ ability and willingness to provide informed consent. 
Exclusion criteria are: patients with a history of anaphy-
laxis drugs, who have renal lesions resultant from systemic 
diseases such as SLE, who are pregnant or may be preg-
nant, who have difficulty controlling blood pressure, or 
who are contraindicated for tonsillectomy as assessed by 
otolaryngologist.
As a rule, following tonsillectomy, all the patients 
whose treatment began during the period of August 2006–
June 2010 received a protocol of single-course steroid 
pulse therapy combined with MZR (Group A), and all the 
patients whose treatment started during the period of July 
2010–March 2013 received a protocol of three-course ster-
oid pulse (Group B). For this analysis, the subjects were 
selected whose proteinuria at the start of the treatment 
was 0.5 g/g Cr or higher and could be followed up for 
12 months. This study was prospective controlled study, but 
not randomized one. The treatment protocol was fixed by 
the period, and informed consent was described all of fac-
tors related this study completely. After treatment of Group 
A was finished, we got the approval of the ethical com-
mittee for this controlled study. The treatment of Group 
B was provided under a condition same as Group A. The 
ethical number of our institutional research committee was 
23-04-162.
Therapeutic Intervention
Bilateral tonsillectomy was performed by an otolaryngolo-
gist, and 1 week later, methylprednisolone (0.5 g/day) was 
administered by drip infusion for 3 days. Simultaneously, 
administration of antiplatelet drugs, antiulcerative drugs, 
sulfamethoxazole–trimethoprim (ST) combination drugs, 
and bisphosphonate was started. Before this step, proce-
dures are identical in all the patients.
Group A
After methylprednisolone pulse, oral administration of 
prednisolone (PSL) 30 mg/day was started. Four weeks 
later, the dose was changed to 30 mg every second day. 
At the same time, MZR 100–150 mg/day once a day was 
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started. PSL was reduced by 5 mg every 4 weeks and 
finally discontinued. ST combination drugs and antiulcer-
ative drugs were discontinued at the time point when the 
dose of PSL became 20 mg every second day. Together 
with the discontinuation of PSL, bisphosphonate was also 
discontinued. MZR and an antiplatelet drug were adminis-
tered continuously for 12 months. Although ordinary oral 
administration of MZR is three times a day with a 50 mg 
dose, in this study, as a rule, we administered it once a day 
with a dose of 150 mg. This was due to the concentration 
of 1 μg/mL being effective for inhibition of the prolifera-
tion of lymphocytes of MZR, and a single administration of 
150 mg is appropriate for obtaining a 1 μg/mL blood peak 
level in humans [13]. The excretion of MZR is a urinary 
type with 81 % of the unchanged rate in urine, and it is thus 
required to adjust the dose at the time of renal dysfunc-
tion. In cases where the eGFR becomes less than 30 mL/
min/1.73 m2, peak level may exceed 3 μg/mL to induce 
hyperuricemia or myelosuppression, which is problematic. 
Thus, we adjusted the MZR level by measuring blood con-
centration so as the peak level did not exceed 3 μg/mL.
Group B
After the methylprednisolone pulse, administration of PSL 
30 mg every second day was started. Two and four months 
later, the same doses of methylprednisolone pulse were 
added. Although the protocol of this steroid pulse therapy 
is nearly the same as a trial conducted by Pozzi et al. [5], 
the drip infusion dose of methylprednisolone differed. In 
this study, it was 0.5 g/day. Starting 6 months after tonsil-
lectomy, the dose of PSL was deceased gradually by 5 mg 
every 4 weeks and finally discontinued. ST combination 
drugs and antiulcerative drugs were discontinued at the 
time point when the dose of PSL became 20 mg every sec-
ond day. Together with the discontinuation of PSL, bispho-
sphonate was also discontinued. Antiplatelet drugs were 
administered continuously for 12 months.
To assess whether antihypertensive drugs have an inhibi-
tory effect on RAS, in cases where the drug was already 
taken when treatment started, the drug was taken continu-
ously and new oral drugs were not allowable for 12 months. 
If blood pressure rose, other antihypertensives such as Ca 
antagonist drugs were administered.
Evaluation of treatment effects (efficacy assessment)
For proteinuria, quantitative determination was con-
ducted as needed by urinary creatinine. A level of less 
than 0.2 g/g Cr was regarded as remission. For hematuria, 
a erythrocyte count of less than five by high-power field 
microscopic examination of urine was regarded as remis-
sion. Hematuria severity was scored with urinary dipstick 
tests. For evaluation of renal function, the glomerular filtra-
tion estimation formula for Japanese made by Japan Kid-
ney Association [eGFR = 194 × (sCr)−1.094 × (Age)−0.287 
× (0.739 if female)] was used for the estimation. During 
the follow-up observation period, blood pressure, general 
blood examinations, biochemical examinations, and urinal-
ysis, marker examinations of infections were conducted to 
confirm the presence or absence of appearance of harmful 
events.
Statistics
For analysis, normality was tested, and a Wilcoxon rank-
sum test was conducted. The uniformity in background 
variables was analyzed by Chi-squared test, and numerical 
parameters were analyzed by repeated measures ANOVA 
for reference. A significance level was determined p < 0.05 
(bilateral). Microsoft Windows SPSS Ver. 11.0 was used 
for statistical software. The data were expressed by mean 
values ± SD.
Results
Table 1 shows the baseline clinical characteristics of 
patients at initiation of treatment. Group B has slightly 
more males, although this was not statistically signifi-
cant. No significant difference was found between groups 
for factors that might influence treatment effects, such as 
number of years from onset to the start of the treatment, 
proteinuria, or renal function. Four histologic grades, I, II, 
III, and IV, were established, corresponding to <25, 25–49, 
50–74, and ≥75 % of glomeruli exhibiting cellular/fibro-
cellular crescents, global sclerosis, segmental sclerosis, or 
fibrous crescents. It was reported this histologic classifica-
tion could identify the magnitude of the risk of progression 
to ESRD and was useful for predicting long-term renal 
outcome in IgA nephropathy [14]. Histologic grade did 
not have a difference between groups. The rates of taking 
RAS inhibitors were 50 % in Group A and 44 % in Group 
B, which were not significant. About the patients with pro-
teinuria more than 1 g/g Cr, the rates of taking RAS inhibi-
tors were 44 % in Group A (n = 23) and 47 % in Group 
B (n = 19). All patients with eGFR < 60 mL/min/1.73 m2 
were taking RAS inhibitors, Group A (n = 12), Group B 
(n = 9).
Figure 1a, b shows variation in proteinuria at the start 
of the treatment and 2, 4, 6, 8, 10, and 12 months later. 
In both groups, significant reduction of proteinuria was 
found at 12 months later compared with baseline. No sig-
nificant difference in the alleviation effect on proteinuria 
was found between groups (Fig. 2). For remission rates 
after 12 months, no significant difference in proteinuria 
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Table 1  Baseline clinical characteristics of patients
p value: a = t test, b = Chi-squared test
Group A
One course of steroid pulse + MZR
Group B
Three courses of steroid pulse
p values
Age (years) 37.7 ± 12.8 35.2 ± 13.8 0.22 a
Gender (M/F) 14/20 19/13 0.14 b
Duration of illness (years) 6.7 ± 5.0 5.5 ± 5.2 0.16 a
Urine OB score 2.50 ± 0.66 2.50 ± 0.72 0.50 a
Proteinuria (g/g Cr) 1.48 ± 0.94 1.27 ± 0.86 0.18 a
Serum creatinine (mg/dL) 0.93 ± 0.38 0.94 ± 0.37 0.52 a
eGFR (mL/min/1.73 m2) 71.5 ± 24.6 77.8 ± 27.0 0.84 a
Serum IgA (mg/dL) 342.5 ± 121.4 319.6 ± 94.5 0.20 a
Histologic graded/II/III/IV) 11/13/7/3 11/14/6/1 0.35 b
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Fig. 1  Variation in proteinuria at the start of the treatment and 2, 4, 
6, 8, 10, and 12 months later. Mean level and standard deviation are 
also presented. In both groups, the proteinuria level decreased signifi-




















Fig. 2  Comparison of the alleviation effect on proteinuria between 
Group A and Group B 12 months after treatment. No significant differ-



















Proteinurina Urine OB Complete remission
Fig. 3  Remission rate of urinary findings 12 months after the initia-
tion of the treatment. No significant difference in the remission rate 
of hematuria or proteinuria, or the complete remission rate of both 
parameters, was found between groups
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and urinary occult blood was found between groups. The 
complete remission rates that both proteinuria and hema-
turia remitted were 55.8 % in Group A and 53.1 % in 
Group B, which were not significantly different (Fig. 3). 
For renal function, Group A showed a significant increase 
in eGFR at 12 months (71.5 ± 24.6 → 75.1 ± 22.2 mL/
min/1.73 m2), whereas Group B tended to show its reduc-
tion (77.8 ± 27.0 → 75.3 ± 27.0 mL/min/1.73 m2) 
(Fig. 4a, b). For the improvement effects on eGFR, the 
effect in Group A was significantly superior (Fig. 5). 
In serum creatinine, Group A showed a significant 
decrease at 12 months (0.93 ± 0.38 → 0.86 ± 0.33 mg/
dL), whereas Group B tended to show its increase 
(0.94 ± 0.37 → 0.96 ± 0.39 mg/dL) (Fig. 6).
We analyzed subgroups who were under RAS inhibi-
tors (Fig. 7). In 17 cases in Group A, eGFR increased 
significantly for 12 months before and after the treatment 
(54.1 ± 14.8 → 58.1 ± 13.6 mL/min/1.73 m2). Fourteen 
cases of Group B tended to increase for 12 months before 
and after the treatment (61.8 ± 29.2 → 62.2 ± 32.0 mL/
min/1.73 m2), but there was no significant difference.
In patients with eGFR < 60 mL/min/1.73 m2, evalua-
tion was also conducted. In 12 cases in Group A, eGFR 
increased significantly for 12 months before and after the 
treatment (46.5 ± 9.4 → 52.9 ± 11.0 mL/min/1.73 m2). 
Nine cases of Group B, conversely, tended to show 
reduction (44.1 ± 8.1 → 42.9 ± 9.6 mL/min/1.73 m2) 
(Fig. 8). In all cases in Group A, eGFR increased after 
12 months. In Group B, there were three cases where 
eGFR decreased by 5 % or higher after 12 months, 
the number of years going on after the initiation of the 
treatment exceeded 12 years in all the cases. In Group 
A, there were three cases where the number of years 




















































Fig. 4  Variation in eGFR at the initiation of the treatment and 2, 4, 6, 
8, 10, and 12 months later. Mean level and standard deviation are also 
presented. In Group A, the eGFR increased significantly 12 months 
after treatment compared with baseline (a). In Group B, no significant 




















(***: p<0.001  Group A vs. Group B) 
Group A
Group B
Fig. 5  Comparison of changes in eGFR at the initiation of the treat-
ment and 12 months later between Group A and Group B. Compared 
with Group B, a significant increase in eGFR was found in Group A
(*: p<0.05 vs. baseline)




















Group A Group B 
Fig. 6  Variation in serum creatinine at the initiation of the treatment 
and 12 months. In Group A, serum creatinine decreased significantly 
12 months after treatment compared with baseline. In Group B, no 
significant difference was found
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12 years and where eGFR increased by 5 % or higher at 
12 months in all cases.
In both the groups, critical complications such as infec-
tions and avascular necrosis of the femoral head were 
absent during the course of the study. In both the groups, 
steroid acne requiring treatment was detected in several 
cases, but they were temporary and mild cases. In one 
case in Group B, administration of antidiabetes drugs was 
required during the course of treatment. No complications 
were associated with tonsillectomy, except for pain.
Discussion
Immunosuppressive therapies after tonsillectomy for IgA 
nephropathy having active lesions were compared. In both 
groups, no significant difference was found in alleviation 
effects on proteinuria or remission rates of urinary find-
ings 12 months after treatment. However, Group A showed 
a significant increase in eGFR. In cases which already 
had renal dysfunction at initiation of treatment, Group 
A showed a significant renal protective effect. In cases in 
Group B where treatment was ineffective, the number of 
years from the disease onset to initiation of the treatment 
tended to be high. The reason for similar remission rates 
and the improvement effect on the renal function obtained 
despite decreasing steroid dose was presumably because of 
the effect of combined MZR.
MZR specifically inhibits inosine monophosphate 
(IMP) dehydrogenase, a rate-controlling enzyme which 
is important for the synthesis of Guanosine monophos-
phate by lymphocytes such as mycophenolate mofetil 
(MMF), and selectively inhibits proliferation of lym-
phocytes, demonstrating an immunosuppressive effect. 
It is known that IMP dehydrogenase acts by chemically 
different mechanisms than MMF. MZR operates on both 
B lymphocytes and T cells so as to inhibit the immune 
reaction to T lymphocyte nondependent antigens and 
activate memory B cells and inhibit the synthesis of 
memory helper T cell and delay hypersensitive reaction. 
Moreover, recently it has been shown that MZR has fur-
ther unique pharmacologic actions. It is reported that in 
the glomerular cells of IgA nephropathy, 14-3-3 protein 
and heat shock protein (HSP) 60 appear. It is shown that 
MZR combines with 14-3-3 protein or HSP60 to increase 
the transcription activity of glucocorticoid receptors and 
then enhance steroid effects [15, 16]. Based on these find-
ings, we considered that the use of MZR in this study 
maintained its direct effect on the glomerular cells in IgA 
nephropathy when the steroid dose was decreased, and 
consequently, the remission rate in one-course pulse was 
equivalent to the three-course pulse.
For influence on the renal function, it is reported that 
mizoribine inhibited infiltration of macrophages into the 
glomerular and the interstitium and then inhibited glo-
merular sclerosis and interstitial fibrotic changes in a dose-
dependent manner in insulin-nonresistant diabetic rats [17]. 
In a comparison study between steroid single therapy and 
steroid + MZR combined therapy in IgA nephropathy, ster-
oid single therapy decreased proteinuria and increased scle-
rotic glomerulus, whereas the combined therapy decreased 
proteinuria and inhibited the increase in sclerotic glomeru-
lus [18]. As its reason, it is presented because MZR inhibits 
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Group A Group B 
(*: p<0.05 vs. baseline)
*
Fig. 7  Variation in eGFR at the initiation of the treatment and 
12 months after treatment about subgroups who were under RAS 
inhibitors. In 17 cases in Group A, eGFR increased significantly for 
12 months before and after the treatment. Fourteen cases of Group B 
tended to increase for 12 months before and after the treatment, but 



















(***: p<0.001 vs. baseline) 












Group A Group B 
n=12 n=9
Fig. 8  Variation in eGFR at the initiation of the treatment and 
12 months after treatment about subgroups with eGFR < 60 mL/
min/1.73 m2. All patients of both groups were taking RAS inhibitors. 
In 12 cases in Group A, eGFR increased significantly for 12 months 
before and after the treatment. Nine cases of Group B, conversely, 
tended to show reduction
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the expression of αSMA in muscle fibroblasts. Moreover, 
it is also reported that MZR inhibits the action of α3β1 
integrin by reacting with HSP60, mentioned above, and 
then decreases the motion capability of fibroblast-specific 
protein (FSP)-1-positive fibroblasts which are involved in 
development of interstitial fibrous change in IgA nephropa-
thy [19].
In addition, recently, it has been demonstrated that acti-
vated macrophages are deeply involved in the pathologic 
conditions of IgA nephropathy. Two lines of M1 and M2 
act as macrophage activation modes. It is known that M1 
is an inflammatory macrophage group activated by inflam-
matory cytokine such as IFN-γ and that M2 is another 
macrophage group activated by cytokines which have an 
anti-inflammatory effect and tissue repair functions such as 
interleukin (IL)-4 and IL-13. Ikezumi et al. [20] reported 
that in IgA nephropathy, M1-type activated macrophages 
are involved in formation of acute active lesions such as 
intratubular proliferation of the glomerulus or cellular cres-
cent form and M2-type activated macrophages are involved 
in formation of chronic lesions such as glomerular sclerosis 
or interstitial fibrous change through syntheses of fibrous 
promotion factors such as TGF-β or CTGF. In a study using 
rat celiac macrophages, they also reported that steroids 
enhanced the expression of CD163, a marker of M2-type 
macrophages, and increased the syntheses of fibrous pro-
motion factors and that the addition of MZR inhibited these 
[21]. As described above, MZR enhances the anti-inflam-
matory effect of steroids and also may inhibit the progress 
of chronic lesions such as fibrous tissue or sclerotic change 
by compensating for the negative effect of steroids.
As for progress of renal fibrous change, it is reported 
that activation of RAS as well as infiltration of mac-
rophages plays an important role [22]. In IgA nephropathy, 
there have been some papers stating that RAS inhibitors 
have protective effects on the renal function [23–25]. In 
this study, there was no difference in the proportion of the 
patients using RAS inhibitors between both the groups, and 
additional administration was not conducted after the ini-
tiation of the treatment. Efficacy and safety of MZR com-
bined with losartan in the treatment of IgA nephropathy 
were reported in RCT [26]. Recently, it has been reported 
that in rat models with unilateral ureteral obstruction, 
MZR combined with a direct renin inhibitor inhibits tubu-
lointestinal fibrous change and inflammation [27]. These 
combined effects were significantly superior to individual 
effects. In this study, because RAS inhibitors were com-
bined for all the patients with eGFR < 60 mL/min/1.73 m2, 
the combination of MZR and RAS inhibitors may enhance 
the renal protective effect.
Although harmful events observed during the follow-
up observation period in this study were mild or slight, 
administration of antidiabetic drugs was required in 
one patient of Group B during the treatment course. It is 
reported that the incidence of diabetes induced by steroids 
ranges from 5 to 25 % and many of the cases occur within 
1 year after the initiation of treatment [28]. In addition, 
steroids increase apoptosis of osteoblasts to inhibit osteo-
genesis and promote differentiation and activation of oste-
oclasts to promote bone absorption and then decrease the 
bone quantity [29]. These complications are reported to be 
dose dependent [30, 31].
It is known that because MZR has a selective inhibi-
tory effect on proliferation of lymphocytes, the rate of 
side effects is lower than that of other immunosuppressive 
drugs [32]. Because MZR in this study was combined, the 
methylprednisolone pulse was conducted only once, and 
the total dose of steroids could be reduced considerably 
without diminishing the treatment effect. Further study 
should be conducted to investigate long-term results of this 
treatment.
We were aware of some limitations of this study. First, 
it was a single-center study with a low number of cases, 
and it was not a randomized controlled trial, which may 
have led to bias. Second, the follow-up period was too short 
to be able to assess several long-term outcomes, i.e., renal 
function. Third, Group B has slightly more males, and in 
Group B, there was less number of patients that took RAS 
inhibitors in comparison with Group A although these were 
not statistically significant. These might be responsible 
for the significant differences in the GFR changes partly. 
Therefore, we analyzed the subgroups who were under 
RAS blockade, and eGFR was increased for significant dif-
ference only in Group A. In patients with eGFR < 60 mL/
min/1.73 m2, evaluation was also conducted. All patients 
of both groups were taking RAS inhibitors. In Group A, 
eGFR increased significantly, but in Group B, conversely, 
it tended to show reduction. However, the number of cases 
we analyzed decreased more, and evaluation about the 
other drugs was not done. Therefore, multicenter stud-
ies with large sample sizes and a long-term follow-up are 
needed to verify these results in the future.
Conclusions
As an immunosuppressive therapy for IgA nephropathy, 
single-course steroid pulse + mizoribine combined ther-
apy was superior to three-course steroid pulse therapy in 
protective effects on renal function. Single-course steroid 
pulse + mizoribine combined therapy is considered a via-
ble treatment method for patients in whom the total dose of 
steroids must be reduced or in those where renal dysfunc-
tion and chronic lesions are present.
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